Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
Precision Medicine Online

Moderna Assures Vaccine De-prioritization in US Doesn't Apply to Cancer

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...

Moderna chair says US assault on science is just beginning

Moderna Inc.’s chairman says the Trump administration’s vaccine policy changes are part of a broader attack on science that ...

Moderna expects $1.9 billion in sales, trims costs forecast for 2025

By Patrick Wingrove Jan 12 (Reuters) - Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, ...